Mesenchymal stem cells overexpressing TRAIL have been described in preclinical studies that improve the biodistribution of TRAIL to enable activity against glioma since the available TRAIL-based therapies do not cross the blood–brain barrier [19]. Here, TNFSF10 is linked to glioma.